London, July 6, 2026, 16:57 (BST)
- Triad Group Plc (LON:TRD) was quoted at 350p/360p after the London close, up 25p, or 7.58%, while FTSE techMARK 100 was down 0.19%.
- The stock printed a new 52-week high of 351.20p during the session; Investors Chronicle quoted free float at 2.24 million shares.
- FY26 revenue rose to £24.8 million and profit before tax to £1.9 million; the proposed final dividend takes the year’s payout to 9p.
Triad Group Plc (LON:TRD) ended Monday with a 350p/360p sell/buy quote after touching a new 52-week high, a sharp move in a stock where the day’s volume was worth only about £69,000 at the quoted midpoint. Hargreaves Lansdown recorded volume of 19,541 shares; Triad has 17,438,579 shares in issue after a 9,191-share option exercise announced last week.
The rise added about £4.36 million to market value, using the 25p marked gain and the new share count. That matters because a small amount of dealing can reset the screen price. Investors Chronicle quoted average volume of 23,600 shares and a 2.24 million-share free float.
The nearest fresh company-specific news was last week’s director dealing. Deputy Executive Chairman Charlotte Rigg bought 8,619 shares at an average 334.15p, a £28,800 purchase. Her interest rose to 1,566,925 shares, or 8.99% of current share capital. Client Services Director Tim Eckes also carried out a Bed and ISA sale and repurchase, leaving his beneficial ownership unchanged at 147,180 shares.
The quote now prices Triad at about £61.9 million, close to Hargreaves Lansdown’s market cap figure. Against basic EPS of 9.92p, the quoted midpoint of 355p stands at 35.8 times FY26 earnings. The proposed total dividend of 9p gives a yield of 2.5% at the same midpoint.
No consensus recommendation and no analyst target price data were available on Stockopedia’s public page. The forecast table below is mechanical: it keeps FY26 net margin, payout ratio and share count steady, then changes revenue.
| Scenario at 355p midpoint | Revenue forecast | EPS forecast | P/E at 355p | DPS forecast | Yield at 355p |
|---|---|---|---|---|---|
| FY26 actual | £24.8m | 9.92p | 35.8x | 9.0p | 2.5% |
| FY27 flat run-rate | £24.8m | 9.92p | 35.8x | 9.0p | 2.5% |
| FY27 +10% revenue, same margins/payout | £27.3m | 10.91p | 32.5x | 9.9p | 2.8% |
| FY27 +20% revenue, same margins/payout | £29.8m | 11.90p | 29.8x | 10.8p | 3.0% |
Triad’s full-year statement gives the case for growth, but it also shows the price risk. Revenue rose 16% to £24.8 million, profit before tax rose to £1.9 million and cash reserves rose to £4.2 million. Gross margin fell to 27.1% from 28.6%, which the company tied to employer national insurance costs, partly offset by lower reliance on contractors.
Executive Chairman Dr John Rigg said “profit converts very efficiently into cash”; Managing Director Adrian Leer said “the new financial year has started well” and that secured work was “at levels higher than previous years.” Investegate
The second valuation check is what EPS would need to do at today’s price if investors want the multiple to fall. The table uses the same 355p midpoint and FY26 basic EPS.
| Implied EPS forecast test at 355p | EPS required | Increase vs FY26 basic EPS |
|---|---|---|
| Current FY26 base | 9.92p | 0% |
| 30x P/E | 11.83p | +19% |
| 25x P/E | 14.20p | +43% |
| 20x P/E | 17.75p | +79% |
Commercially, Triad said it won major contracts at the Met Office and Office for Product Safety & Standards, with nearly £20 million in award value; it also cited a multi-million-pound award at the Foreign, Commonwealth & Development Office and a new client win at the Medicines and Healthcare products Regulatory Agency.
Consultant numbers are the next line to watch. The company said permanent consultant numbers rose to 170 at year-end from 147 and average full-time permanent consultants rose to 157 from 131. More fee-earning staff supports revenue; it also raises fixed costs if public-sector digital work slows.
